An Assessor-Blind, Randomized, Three-Treatment, Three- Period, Single-Dose, Crossover, Bioequivalence Study of INTG8 of Intas Pharmaceuticals Limited, India to Forteo (Lilly USA, LLC) and Forsteo (Eli Lilly Nederland B.V., The Netherlands) in Healthy Men and Postmenopausal Women after Subcutaneous Administration
Latest Information Update: 18 Jan 2023
At a glance
- Drugs Teriparatide (Primary)
- Indications Fracture; Osteoporosis
- Focus Pharmacokinetics
- Sponsors Intas Pharmaceuticals
- 01 Jan 2023 Primary endpoint has been met (AUC from time zero extrapolated to infinity (AUC0-), as per Results published in the Osteoporosis International
- 01 Jan 2023 Primary endpoint has been met (area under the curve (AUC) from time zero to t (AUC0-t), as per Results published in the Osteoporosis International
- 01 Jan 2023 Primary endpoint has been met (Maximum serum concentration (Cmax), as per Results published in the Osteoporosis International